NCT04741711 AMBulatory UltraSound for Heart Failure Management
| NCT ID | NCT04741711 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 182 participants |
| Start Date | 2023-05-15 |
| Primary Completion | 2026-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 182 participants in total. It began in 2023-05-15 with a primary completion date of 2026-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
AMBUSH study is a multicenter randomized, controlled, open-label clinical trial (PROBE (Prospective Randomized Open Blinded End-point) type). The main objective of AMBUSH study is to assess the effect of therapeutic management guided by pulmonary ultrasound and the assessment of the inferior vena cava in patients with heart failure seen in an ambulatory (outpatient) setting on a mixed clinical-biological endpoint (including variations of natriuretic peptides - NtProBNP) at 30 days.
Eligibility Criteria
Inclusion Criteria: * Male or female aged 18 and over * Heart failure (regardless of left ventricular ejection fraction) * Diagnosis of heart failure established more than 3 months ago * Absence of significant clinical signs of congestion on clinical examination (absence of crackles and lower limbs oedema greater than perimalleolar oedema) * Affiliation to social security * Receiving complete information about research organization and signed informed consent. Exclusion Criteria: * Natriuretic peptides result, carried out during the previous 30 days, available at the inclusion consultation * Pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis. * Suspicion of cardiac amyloidosis or proven amyloidosis, * Patient with severe primary heart valve disease * Pregnant woman, parturient or nursing mother * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * Person deprived of liberty by a judicial or administrative decision, * Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04741711 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04741711 currently recruiting?
Yes, NCT04741711 is actively recruiting participants. Contact the research team at n.girerd@chru-nancy.fr for enrollment information.
Where is the NCT04741711 trial being conducted?
This trial is being conducted at Besançon, France, Mulhouse, France, Reims, France, Thionville, France and 1 additional location.
Who is sponsoring the NCT04741711 clinical trial?
NCT04741711 is sponsored by Central Hospital, Nancy, France. The trial plans to enroll 182 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.